Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 16 to 70 years at the time of screening, any gender
• People with a good general health and activity level, as measured by a standard performance scale (ECOG score of 0 or 1)
• People newly diagnosed with a type of blood cancer called Ph-negative B-cell acute lymphoblastic leukaemia (B-ALL), who are in their first remission after chemotherapy but still have a small detectable amount of leukaemia remaining in the bone marrow (called MRD-positive)
• People newly diagnosed with a related type called Ph-positive B-ALL, who are also in their first remission but still have a small detectable amount of leukaemia remaining
• People whose leukaemia cells tested positive for a protein called CD19 at the time of diagnosis
• People whose liver, kidneys, heart, lungs, and blood clotting function all fall within acceptable ranges as measured by specific blood and other tests
• People who meet the trial centre's requirements for a blood cell collection procedure (leukapheresis), with no medical reasons preventing this
• People who are willing to take part and have signed a consent form agreeing to join the study

Who may not be able to join:

• People who have previously received CAR-T cell therapy
• People with an inherited bone marrow failure condition or any other known bone marrow failure syndrome
• People with active autoimmune diseases that currently require treatment
• People who test positive for certain infections, including active hepatitis B, hepatitis C, syphilis, HIV, or who have detectable levels of Epstein-Barr virus (EBV) or cytomegalovirus (CMV) in their blood
• People who have an active infection at the time of screening
• People who have had another type of cancer in the past five years, unless a doctor determines the risk of it returning is very low or the person has been cancer-free for more than five years after curative treatment
• People with significant heart problems, including severe heart failure, serious irregular heartbeat, uncontrolled high blood pressure or high blood pressure in the lungs, unstable chest pain, a heart attack or heart surgery within the past six months, significant heart valve disease, or other heart conditions a doctor considers unsuitable
• People with a history of epilepsy, cerebellar disease, or other active disorders affecting the brain or nervous system
• People with uncontrolled diabetes
• People who have had a significant blood clot in a vein or in the lungs within the past six months that is not well controlled
• People with a known allergy or sensitivity to any ingredient in the study treatment
• People who have received a live vaccine within six weeks before screening
• People whose life expectancy is less than three months
• People who have taken part in another clinical trial involving experimental treatments within three months (or within a specified timeframe for approved drugs) before the cell infusion, or who plan to join another trial or receive other cancer treatments during the study
• People with any other condition that the trial doctor considers makes participation unsuitable

Important: Always verify eligibility with the trial site directly before applying.